LXCHEM - Laxmi Organic
📢 Recent Corporate Announcements
Laxmi Organic Industries has announced that its Chief Financial Officer, Mr. Mahadeo Karnik, will resign effective April 13, 2026. To manage the transition, the company has appointed Executive Director Mr. Harshvardhan Goenka as the Interim CFO starting April 14, 2026. Notably, the company has already identified a permanent successor who is expected to join by June 15, 2026. This clear timeline for succession helps mitigate concerns regarding leadership gaps in the finance department.
- CFO Mahadeo Karnik to step down from his role effective April 13, 2026.
- Executive Director Harshvardhan Goenka, with 13+ years of experience, to serve as Interim CFO from April 14, 2026.
- A permanent successor has been identified and is tentatively expected to join the firm on June 15, 2026.
- The transition period under interim leadership is expected to last approximately 60 days.
Laxmi Organic Industries has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the period ending March 31, 2026. The certificate, issued by MUFG Intime India Private Limited, confirms that the company has adhered to all necessary protocols regarding the dematerialization of securities. Interestingly, the Registrar noted that no requests for dematerialization or rematerialization were actually received during this specific quarter. This is a standard administrative filing required for all listed entities in India.
- Compliance certificate filed for the quarter ended March 31, 2026
- Issued by Registrar and Share Transfer Agent, MUFG Intime India Private Limited
- Confirmed zero requests for dematerialization or rematerialization were received during the quarter
- Ensures adherence to SEBI (Depositories and Participants) Regulations, 2018
Laxmi Organic Industries has allotted 63,694 equity shares of face value ₹ 2 each following the exercise of options under its ESOP 2020 scheme. The allotment includes 14,154 shares at an exercise price of ₹ 2 and 49,540 shares at ₹ 100 per share. Consequently, the company's paid-up share capital has increased to approximately ₹ 55.44 crore. These new shares will rank pari passu with existing equity shares, meaning they carry the same rights as current holdings.
- Allotment of 63,694 equity shares of ₹ 2 face value under the ESOP 2020 scheme.
- Exercise prices were set at ₹ 2 for 14,154 shares and ₹ 100 for 49,540 shares.
- Total paid-up share capital increased to ₹ 55,44,23,134 from ₹ 55,42,95,746.
- Total outstanding equity shares post-allotment stand at 27,72,11,567.
Laxmi Organic Industries Limited has informed the stock exchanges that its trading window will be closed starting April 1, 2026. This closure is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction applies to all Designated Persons and their immediate relatives ahead of the declaration of audited financial results for the quarter and year ending March 31, 2026. The window will reopen 48 hours after the financial results are officially announced.
- Trading window closure begins on Wednesday, April 01, 2026.
- Closure is in preparation for the audited financial results for Q4 and FY ending March 31, 2026.
- Restriction applies to all Designated Persons and their immediate relatives as per the Company's Code of Conduct.
- The window will remain closed until 48 hours after the conclusion of the Board Meeting for result approval.
- The specific date for the Board Meeting to declare results will be announced in due course.
Laxmi Organic Industries Limited has successfully passed a special resolution for the re-appointment of Dr. Rajiv Banavali as an Independent Director. The resolution, conducted via postal ballot, received overwhelming support with 99.929% of the 205.9 million valid votes cast in favor. Dr. Banavali's second term will run for two years, starting from May 18, 2026, until May 17, 2028. This outcome reflects strong shareholder confidence in the company's existing board composition and governance structure.
- Special resolution passed for re-appointment of Dr. Rajiv Banavali as Independent Director.
- The two-year term is effective from May 18, 2026, to May 17, 2028.
- 205,789,451 votes (99.929%) were cast in favor of the resolution.
- Only 146,065 votes (0.071%) were cast against the proposal.
- A total of 345 members participated in the remote e-voting process.
Maharashtra State Electricity Distribution Company Limited (MSEDCL) has filed an appeal before the Appellate Tribunal for Electricity (APTEL) challenging a previous order that was ruled in favor of Laxmi Organic Industries. The appeal includes an application for a 116-day delay condonation, which is currently pending admission by the tribunal. If the appeal is admitted and a stay is granted, the company faces a maximum potential financial exposure of ₹407.27 million plus interest. The company believes the appeal is unsustainable as the matter was already technically adjudicated by the Maharashtra Electricity Regulatory Commission (MERC).
- MSEDCL is challenging the MERC Final Order dated September 17, 2025, which was originally in favor of the company.
- Maximum potential financial impact is quantified at ₹407.27 million plus applicable interest.
- The appeal is currently at the pre-admission stage with a 116-day delay condonation application pending.
- The company maintains that the appeal is not sustainable based on previous technical examinations by MERC.
CRISIL has downgraded Laxmi Organic Industries' long-term rating to 'AA-/Negative' from 'AA/Negative' while maintaining a Negative outlook. The downgrade is driven by a steeper-than-expected decline in revenue and profitability, with 9M FY26 operating margins falling to 4.4% from 9.5% YoY. While the company maintains a healthy capital structure with gearing at 0.17x, the return on capital employed (RoCE) is expected to drop to low single digits this fiscal due to high capex and lower earnings.
- Long-term bank facilities downgraded to 'CRISIL AA-/Negative'; short-term rating reaffirmed at 'CRISIL A1+'
- 9M FY26 revenue declined 9% YoY to ₹2,071 crore, with specialty chemical sales dropping 22%
- Operating margins compressed to 4.4% from 9.5% due to pricing pressure and phase-out of high-margin products
- Interest coverage ratio deteriorated significantly to 6.00x from 18.68x in the previous year
- Company is executing a major ₹700 crore capex in FY26, with ₹475 crore already deployed by December 2025
Laxmi Organic Industries Limited has initiated a postal ballot process to seek shareholder approval for the re-appointment of Dr. Rajiv Banavali as an Independent Director. The proposed re-appointment is for a second term of 2 years, effective from May 18, 2026, to May 17, 2028. The voting process will be conducted entirely through electronic means, with the e-voting period spanning from February 7 to March 8, 2026. Results of the ballot are expected to be declared by March 10, 2026, following the scrutiny of votes.
- Proposed re-appointment of Dr. Rajiv Banavali as Independent Director for a 2nd term of 2 years
- New term duration set from May 18, 2026, until May 17, 2028
- E-voting period scheduled from February 7, 2026 (9:00 AM) to March 8, 2026 (5:00 PM)
- Cut-off date for determining shareholder eligibility was January 30, 2026
- Final results of the postal ballot to be announced on or before March 10, 2026
Laxmi Organic Industries reported a weak Q3 FY26 with revenue from operations declining 8% YoY to ₹7,068.72 million. Profit After Tax (PAT) fell 28.7% YoY to ₹198.31 million, despite being supported by significant one-time items and accounting changes. The company changed its depreciation method to Straight Line (SLM), without which it would have reported a loss before tax of ₹53.16 million for the quarter. Additionally, the bottom line was aided by a ₹407.27 million reversal of electricity-related liabilities and a ₹97.18 million deferred tax credit from adopting a new tax regime.
- Revenue from operations decreased to ₹7,068.72 million in Q3 FY26 from ₹7,678.72 million in Q3 FY25.
- Profit After Tax (PAT) declined to ₹198.31 million compared to ₹278.15 million in the same quarter last year.
- Change in depreciation method from WDV to SLM prevented a reported pre-tax loss of ₹53.16 million for the quarter.
- One-time reversal of ₹407.27 million in electricity charges (MSEDCL) recorded under other operating income.
- Adoption of lower tax rate (25.17%) resulted in a one-time deferred tax reversal of ₹97.18 million.
Laxmi Organic reported a 9% YoY revenue decline and a 33% drop in EBITDA to ₹50 crores for Q3 FY26, though this included a ₹40.7 crore one-time litigation gain. Excluding one-timers, adjusted EBITDA stood at a weak ₹14 crores as the Specialties segment saw a 30% revenue drop due to price moderation and product phase-outs. The Essentials segment faced subdued spreads, though ethyl acetate margins are recovering toward $130 as acetic acid prices rebound from lows. Management expects the major Dahej Phase 2 expansion to be completed by the end of Q4 FY26, which is critical for future volume growth.
- Reported EBITDA of ₹50 crores includes a ₹40.7 crore one-time gain from a favorable Supreme Court order on wheeling charges.
- Specialties revenue declined 30% YoY, impacted by a 10% hit from an agrochemical intermediate phase-out and 12% from price moderation.
- Essentials segment revenue fell 6% YoY despite stable volumes, reflecting a 20% plus drop in acetic acid feedstock prices over two years.
- Ethyl acetate spreads improved from $90-$100 to approximately $130 as acetic acid prices rebounded to $360-$380 in December.
- Phase 2 of the Dahej facility, the company's largest capex project, is on track for completion by the end of Q4 FY26.
Laxmi Organic Industries Limited has released the audio recording of its investor and analyst meet held on January 30, 2026. The meeting focused on the company's financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is in compliance with SEBI Listing Obligations and Disclosure Requirements. Investors can access the recording via the provided link to understand management's commentary on recent results and future outlook.
- Recording of the Q3 and 9M FY26 investor meet held on Jan 30, 2026, is now available for public access
- The call discussed performance metrics for the nine-month period ending December 31, 2025
- Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
- The meeting was held at 14:00 hours IST on the same day as the disclosure
Laxmi Organic Industries (LXCHEM) presented its Q3 and 9M FY26 performance, highlighting a revenue base of approximately $300 million and a strategic shift toward a customer-centric business model. The company is leveraging its new $8 million Innovation Centre in Navi Mumbai to drive high-margin growth in its Specialties segment, including fluorospecialties. With a massive 116-acre brownfield site in Dahej currently less than 20% occupied, the company has significant long-term capacity for expansion. The Essentials business maintains its market leadership in India, supported by a 25% green power mix.
- Annual revenue stands at approximately $300 million with a portfolio of 50+ products serving 650+ customers.
- Invested $8 million in a new 30,000 sq. ft. Innovation Centre to enhance R&D and process engineering capabilities.
- Significant expansion potential at the Dahej site (116 acres) with current land occupancy below 20%.
- Successfully completed ISCC Plus certification for the Dahej site in November 2025, boosting sustainability credentials.
- Specialties segment now includes 30+ Diketene derivatives and is scaling up fluorination and mercaptan chemistries.
Laxmi Organic Industries has approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board also approved the re-appointment of Dr. Rajiv Banavali as an Independent Director for a second term of two years, starting May 18, 2026. Dr. Banavali brings over 38 years of global experience in the chemicals sector, including leadership roles at WestRock and Honeywell. The re-appointment is subject to shareholder approval through a postal ballot process.
- Approved Unaudited Consolidated and Standalone Financial Results for Q3 and Nine Months ended Dec 31, 2025.
- Re-appointed Dr. Rajiv Banavali as Independent Director for a second term from May 18, 2026, to May 17, 2028.
- Dr. Banavali holds a Ph.D. in chemistry and has 38+ years of experience in material sciences and innovation.
- The Board meeting was conducted over a three-hour duration, concluding at 20:00 hours IST.
- Shareholder approval for the director's re-appointment will be sought via a postal ballot notice.
Laxmi Organic Industries has approved the re-appointment of Dr. Rajiv Banavali as an Independent Director for a second term of two years, effective from May 18, 2026, to May 17, 2028. Dr. Banavali is a veteran in the chemical industry with over 38 years of experience, including leadership roles at global firms like WestRock, Honeywell, and Huntsman. His deep expertise in material sciences and R&D innovation will continue to support the company's strategic growth. The board also approved the financial results for the quarter and nine months ended December 31, 2025, during the same meeting.
- Dr. Rajiv Banavali re-appointed for a second term of 2 years starting May 18, 2026.
- Director brings over 38 years of chemical sector experience and a Ph.D. in Chemistry.
- Previous leadership roles include Senior VP at WestRock and positions at Rohm & Haas and Honeywell.
- The board concurrently approved the unaudited standalone and consolidated Q3 FY26 financial results.
- Re-appointment is subject to shareholder approval through a postal ballot process.
Laxmi Organic Industries approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board also approved the re-appointment of Dr. Rajiv Banavali as an Independent Director for a second two-year term, effective from May 18, 2026, to May 17, 2028. Dr. Banavali is a veteran in the chemical industry with over 38 years of experience, including senior roles at WestRock and Honeywell. The company will initiate a postal ballot to seek shareholder approval for this re-appointment.
- Approved Unaudited Standalone and Consolidated Financial Results for Q3 and 9M ended December 31, 2025.
- Re-appointed Dr. Rajiv Banavali as Independent Director for a second term of 2 years starting May 2026.
- Dr. Banavali brings 38+ years of global chemical industry experience and a Ph.D. from the University of Missouri.
- The board meeting lasted 3 hours, concluding at 20:00 IST on January 29, 2026.
Financial Performance
Revenue Growth by Segment
Total revenue for FY25 was INR 29,446.06 Mn, a 4.26% increase YoY. In H1 FY25, the Specialty segment grew 15.9% to INR 475 Cr, while the Essentials segment grew 4.4% to INR 1,014 Cr. However, H1 FY26 saw a 6.4% YoY decline to INR 1,393 Cr due to pricing pressures and a 20% decline in Specialty revenue during Q2 FY26.
Profitability Margins
Gross margins were 33.1% in Q2 FY26, down from 35.8% in Q2 FY25. Net profit for FY25 was INR 1,180.21 Mn, a 7.34% decrease from INR 1,273.70 Mn in the previous year. PAT margin for Q2 FY26 stood at 1.6%, a decline of 207 bps YoY.
EBITDA Margin
FY25 EBITDA was INR 3,077.17 Mn, up 7.29% YoY. However, the EBITDA margin significantly contracted to 4.9% in H1 FY26 from 9.8% in H1 FY25. Q2 FY26 adjusted EBITDA margin was 5.6%, reflecting a 405 bps YoY decline due to lower realizations and product phase-outs.
Capital Expenditure
The company is executing a total capex of INR 1,100 Cr between FY25 and FY28. Phase I (FY25-26) involves INR 800-850 Cr for doubling diketene derivatives and adding 70,000 MTPA each of Ethyl Acetate and n-butyl acetate. Phase II (FY27-28) involves INR 300-350 Cr for further specialty and essential expansions.
Credit Rating & Borrowing
CRISIL AA/Negative (outlook revised from Stable). Short-term rating is CRISIL A1+. Gearing is healthy at 0.17x as of September 2025. Interest coverage ratio deteriorated to 7.29x in H1 FY26 from 15.02x in H1 FY25 due to the sharp decline in profitability.
Operational Drivers
Raw Materials
Key raw materials include Acetic Acid (linked to natural gas prices) and Ethyl Alcohol/Ethanol (derived from sugarcane molasses or grain). These represent a significant portion of the cost structure, with Essentials revenue (72% of total) being highly sensitive to feedstock price links.
Import Sources
The company imports raw materials such as acetic acid and ethyl alcohol, though specific countries are not listed beyond general mentions of global supply dynamics.
Capacity Expansion
Essentials capacity utilization is currently 90-95%. Planned expansion includes doubling diketene derivatives capacity to become a top 3 global producer and adding 70,000 MTPA of Ethyl Acetate and 70,000 MTPA of n-butyl acetate by H2 FY26.
Raw Material Costs
Raw material costs are highly volatile; for instance, Q2 FY26 COGS was INR 4,679 Mn against revenue of INR 6,997 Mn (approx. 66.8% of revenue). Procurement strategies include diversifying the supplier base and Alternate Vendor Development (AVD) to mitigate price spikes.
Manufacturing Efficiency
Essentials and diketene derivative units are operating at 90-95% and 100% utilization respectively. Efficiency is driven by an 'operational excellence journey' to increase throughput from existing assets.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be driven by doubling diketene derivative capacity to reach a top 3 global ranking, ramping up the fluorochemicals business to 40-60% of peak revenue (targeting INR 80-100 Cr), and diversifying the Essentials portfolio with new n-butyl acetate capacity. The company aims for an asset turn of 1.2x on new capex.
Products & Services
Ethyl Acetate, Diketene Derivatives, Fluorochemicals, n-butyl acetate, and specialty chemicals used in pharmaceuticals, agrochemicals, paints, and packaging.
Brand Portfolio
Laxmi Organic Industries Limited (LXCHEM).
New Products/Services
Introduction of n-butyl acetate (70,000 MTPA) and expansion into new diketene derivatives. Fluorochemicals are expected to contribute significantly as the capacity ramps up to peak levels.
Market Expansion
Targeting global markets to become a top 3 producer in specific chemistries. Expansion is focused on the Dahej and Lote facilities with production commencement expected in H2 FY26.
Market Share & Ranking
Strong market position in Essentials and Specialty; aiming for Top 3 globally in Ketene and Diketene derivatives.
Strategic Alliances
Absorption of Yellowstone Fine Chemicals Private Limited was completed to consolidate operations.
External Factors
Industry Trends
The global chemical industry is currently facing supply-side overcapacities and pricing pressure. LXCHEM is responding by optimizing costs and restructuring to remain competitive against subscale assets.
Competitive Landscape
Facing competition from global players; noted that Sipchem (Middle East) recently took 100,000 tonnes of capacity offline, affecting market spreads.
Competitive Moat
Moat is built on complex chemistries, high R&D requirements, and high capital entry barriers in the Specialty segment (72% of EBITDA). Sustainability is supported by a diversified end-user base where no single segment exceeds 30% of revenue.
Macro Economic Sensitivity
Highly sensitive to global supply-demand dynamics and natural gas prices, which dictate the cost of acetic acid, a primary feedstock.
Consumer Behavior
Demand signals remain demanding due to regional dynamics and cost-optimization efforts by end-users in pharma and agrochemicals.
Geopolitical Risks
Geopolitical tensions are identified as a supply chain risk that could disrupt production schedules and delivery to overseas locations.
Regulatory & Governance
Industry Regulations
Operations are subject to Industry-specific laws, Labour laws, and environmental regulations. The company uses an automated internal compliance management tool to track statutory obligations.
Environmental Compliance
Ongoing changes in environmental norms necessitate significant compliance investments, managed by a Risk Management and ESG Governance Committee.
Taxation Policy Impact
The company paid INR 165 Mn in direct taxes in H1 FY26. The effective tax rate is subject to standard corporate tax laws in India.
Legal Contingencies
No significant legal weaknesses or material departures from accounting standards were reported in the FY25 annual report. Specific pending court case values were not disclosed.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timing of the recovery in operating margins, which halved to 4.9% in H1 FY26. Sustained pricing pressure and potential delays in capex execution (INR 1,100 Cr) are key monitorables.
Third Party Dependencies
Dependence on imported acetic acid and ethanol makes the company vulnerable to supplier disruptions and global pricing cycles.
Technology Obsolescence Risk
Delayed adoption of emerging technologies is identified as a risk that could reduce competitiveness; mitigated by ongoing R&D and technology absorption initiatives.
Credit & Counterparty Risk
Receivables and credit exposure are managed through a diversified customer base with no single client exceeding 10% of revenue, reducing individual counterparty risk.